Laurus Labs Q2 FY27: Revenue surges 33% to ₹2,206 Cr, Net Profit up 126%
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr, up 31%, driven by CDMO and Affordable Medicines. Q2 FY27 revenue grew 33% to ₹2,206 Cr. EBITDA surged 72% to ₹1,406 Cr for H1, with net profit up 126% to ₹809 Cr. The company announced strategic acquisitions in oligonucleotide and peptide-resin technology to strengthen its CDMO offering.
The significant increase in financial performance and strategic acquisitions in high-growth areas like oligonucleotides and peptides are likely to have a substantial positive impact on the company's future growth and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and net profit for both the half-year and the second quarter, along with strategic acquisitions to enhance its CDMO capabilities.
Laurus Labs Limited announced its financial results for the quarter and half-year ended September 30, 2026, presenting a strong performance across key metrics. The company reported a consolidated revenue of ₹4,233 crore for the half-year ended September 30, 2027, marking a significant 31% increase compared to the same period last year. This growth was primarily driven by the robust performance of the CDMO segment, which saw a 71% increase in revenue to ₹1,774 crore, and a healthy 13% growth in the Affordable Medicines (AM) division, contributing ₹2,459 crore.
For the second quarter of FY27, the company's revenue stood at ₹2,206 crore, a substantial 33% year-on-year increase. The CDMO segment continued its strong momentum, with revenue growing by 75% to ₹904 crore in Q2 FY27. The Affordable Medicines division also demonstrated resilience, with revenue rising by 15% to ₹1,302 crore.
Profitability saw a significant boost, with EBITDA for the half-year reaching ₹1,406 crore, a 72% increase year-on-year, resulting in an EBITDA margin of 33.2%. Net profit for the half-year surged by 126% to ₹809 crore. In the second quarter, EBITDA increased by 78% to ₹762 crore, with margins expanding to 34.5%, and net profit recorded a 126% jump to ₹441 crore.
The company also highlighted strategic investments in two technology platforms to enhance its Integrated CDMO offering: oligonucleotides and peptide-resins. Laurus Labs has entered into a definitive agreement to acquire a 60% stake in Galenvs, specializing in oligonucleotide synthesis and purification, and plans to acquire a 52% stake in SI &C Resins, a company focused on peptide-resin technology. These acquisitions are expected to expand Laurus's position in the fast-growing oligonucleotide and peptide markets.
Capital expenditure for the half-year amounted to ₹864 crore, representing 20% of revenue, reflecting sustained investment in expanding the manufacturing network and niche capabilities. The company is investing over ₹3,000 crore over FY27 and FY28 across its manufacturing network and capability expansion.
An investor and analyst call was scheduled for October 29, 2026, at 5:00 PM IST, to discuss these results and the company's strategic initiatives.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.